- Raised $800k grant, May 2015
- Raised $1M grant, Feb 2015
- Raised $1.2M funding round
About
Immune System Key (ISK) is engaged in the discovery and development of treatments for malignant cancers and autoimmune diseases, with a primary focus on treating patients with acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer. Its assets are based on novel human-secreted peptides that were discovered by the company's founders. ISK's lead compound is Nerofe, which offers the potential to inhibit all three biological processes that support cancer progression. In phase-1 testing, researchers demonstrated induction of a strong anti-angiogenic effect and activation of anticancer immune response. In addition, in-vitro experiments indicate that Nerofe may have a strong inhibitory effect on cancer cell proliferation. Nerofe was granted orphan status by the FDA for the treatment of AML. The company has also developed a novel marker whose presence in a patient's biopsy can help predict the success of treatment with Nerofe.
Funding history · 6 rounds · $3.7M total
Q&A
- What is Immune System Key's primary focus in drug development?
- Immune System Key (ISK) is focused on the discovery and development of treatments for malignant cancers and autoimmune diseases, specifically targeting acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer.
- What is Immune System Key's lead compound and its key features?
- Immune System Key's lead compound is Nerofe, which aims to inhibit three biological processes supporting cancer progression. Phase-1 testing showed a strong anti-angiogenic effect and activation of anticancer immune response. Nerofe has been granted orphan status by the FDA for AML treatment.
- How many employees does Immune System Key currently have?
- Immune System Key has 1-10 employees.
- Who are the co-founders of Immune System Key?
- The co-founders of Immune System Key are Dr. Yoram Devary, who serves as Co-founder, Chairman & CTO, and Prof. Uziel Sandler, who is Co-founder, Vice-Chairman & CEO.
- What is the total amount of funding Immune System Key has raised?
- Immune System Key has raised a total of $3,700,000.
- When was Immune System Key founded?
- Immune System Key was founded in February 1992.
- Has Immune System Key received any grants from the Israel Innovation Authority?
- Yes, Immune System Key received grants from the Israel Innovation Authority in January 2016 and January 2017.
- What is the product stage of Immune System Key's developments?
- Immune System Key's developments are in the clinical trial stage.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunesk.com |
|---|---|
| linkedin.com/company/2619379 |
Identifiers & details
| Former names | ThymuFight |
|---|---|
| Founded | 1992-2 |
| Employees (exact) | 2 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | immunesk.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|